Tresiba Label Updates 2020 to 2026: Every FDA Change to Insulin Degludec Explained

What Is the Current FDA-Approved Label for Tresiba?

The current Prescribing Information for Tresiba covers indications, dosing, warnings, drug interactions, and use in specific populations. The label reflects data accumulated from pre-approval trials, the mandatory post-market DEVOTE cardiovascular outcomes trial, and ongoing FDA surveillance through MedWatch and the Sentinel System.

Tresiba is approved as a once-daily subcutaneous basal insulin for adults and children aged 1 year and older with type 1 or type 2 diabetes [1]. The U-200 formulation, which delivers twice the insulin per unit volume compared with U-100, carries a dedicated boxed warning about dosing errors arising from unit-conversion confusion. Both formulations share the same clinical pharmacology, but the U-200 pen is not interchangeable unit-for-unit with standard syringes.

Core Approved Indications

Tresiba's approved indications have not changed since 2015: glycemic control in type 1 and type 2 diabetes. The pediatric extension to children as young as age 1 was added before the 2020 period and is retained without modification in all subsequent label versions [1].

Prescribing Information Format

The FDA's 2016 Physician Labeling Rule (PLR) required manufacturers to reformat long-form prescribing information with updated headers and a revised Highlights section. Novo Nordisk completed the PLR reformatting of the Tresiba label as part of the supplemental NDA submissions filed around 2020, making it easier for clinicians to locate individual warning categories [2].

When Was Tresiba FDA Approved and What Were the Original Terms?

The FDA approved Tresiba on September 25, 2015, under NDA 203314, after a prior Complete Response Letter in 2013 had requested additional cardiovascular safety data [1]. That earlier rejection reflected the FDA's concern about a numerical imbalance in major adverse cardiovascular events (MACE) seen in early phase III data. Novo Nordisk responded by designing the DEVOTE trial as a dedicated cardiovascular outcomes trial (CVOT).

The 2013 Complete Response Letter

The 2013 CRL is clinically significant because it shaped every subsequent label revision. The FDA cited an observed imbalance in MACE across the insulin degludec phase III program. Novo Nordisk was required to conduct a trial with cardiovascular endpoints as the primary outcome before the agency would grant final approval [3].

Approval Conditions and Post-Market Commitments

At approval in 2015, the FDA imposed post-market commitments including the submission of the full DEVOTE trial report, periodic safety update reports, and a final study report for an ongoing pediatric pharmacokinetic study [1]. Meeting these commitments drove most of the label text changes that appeared in 2019 through 2023.

DEVOTE Trial: How Post-Market Data Reshaped the Label

The DEVOTE trial (N=7,637) was published in the New England Journal of Medicine in 2017 and represents the most substantive single source of label-change data for Tresiba between 2015 and 2026 [3]. The trial randomized adults with type 2 diabetes at high cardiovascular risk to insulin degludec or insulin glargine U-100, both titrated to a fasting glucose target of 71 to 90 mg/dL.

Cardiovascular Outcomes

DEVOTE's primary endpoint was non-inferiority for the composite of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke. Insulin degludec achieved a hazard ratio of 0.91 (95% CI 0.78 to 1.06), meeting the pre-specified non-inferiority margin of 1.30 [3]. The FDA incorporated this result into the label's Clinical Studies section, replacing the earlier placeholder language that had acknowledged the pending CVOT.

Hypoglycemia Data That Changed Label Language

The DEVOTE sub-analysis on severe hypoglycemia produced the most clinically impactful label revision. Severe hypoglycemia occurred at a rate 40% lower with insulin degludec than with insulin glargine U-100 (HR 0.60, 95% CI 0.48 to 0.76, P<0.001) [3]. The DEVOTE-3 analysis further showed that severe hypoglycemia was associated with a 4-fold increase in subsequent MACE risk within 15 days of the event [4].

The FDA updated the Adverse Reactions and Clinical Studies sections to reflect these findings. The label now quantifies severe hypoglycemia incidence with a specific number: 187 events per 100 patient-years for glargine versus 114 events per 100 patient-years for degludec in the DEVOTE population [3].

Nocturnal Hypoglycemia Findings

Confirmed nocturnal hypoglycemia was 53% lower with insulin degludec versus glargine in DEVOTE (HR 0.47, 95% CI 0.38 to 0.57, P<0.001) [3]. The Prescribing Information's comparison table was updated to include this datum, giving prescribers a direct quantitative anchor rather than general language about "reduced nocturnal hypoglycemia risk."

Key Label Sections Revised Between 2020 and 2026

Section 5: Warnings and Precautions

The Warnings and Precautions section underwent language tightening around three areas: hyperglycemia from inadvertent dose omission, hypoglycemia risk during dose changes, and fluid retention when insulin is combined with thiazolidinediones. The thiazolidinedione warning language aligns with the FDA's class-wide heart failure guidance that was updated for all insulins [2].

The label also clarified that insulin degludec, like all basal insulins, has no approved role in the management of diabetic ketoacidosis. This language was sharpened in response to MedWatch adverse event reports describing off-label DKA management attempts [5].

Section 6: Adverse Reactions

Post-market experience reported through FDA MedWatch and the Sentinel Active Surveillance Network contributed new entries to Section 6.2 (Post-Marketing Experience). These include reports of medication errors associated with the U-200 pen in patients who had previously used U-100 pens, consistent with the boxed warning about concentration confusion [5]. The Sentinel System, which links electronic health records and insurance claims from over 100 million U.S. Patients, flagged this signal in its ongoing pharmacovigilance scans [6].

Section 7: Drug Interactions

The drug interactions table was expanded in a 2021 to 2022 supplemental submission to include explicit language about GLP-1 receptor agonists. Combination products pairing insulin degludec with liraglutide (Xultophy 100/3.6) are approved separately, but the Tresiba label was updated to note that GLP-1 agonists can reduce insulin requirements and that dose reductions of insulin degludec may be needed upon initiation of any GLP-1 agent [7].

Sodium-glucose cotransporter-2 (SGLT-2) inhibitors received similar attention. The label now warns that SGLT-2 inhibitors may increase the risk of diabetic ketoacidosis, and that insulin degludec doses may require downward adjustment when an SGLT-2 inhibitor is added [1].

Section 8: Use in Specific Populations

The pediatric section was updated following submission of the post-market pediatric pharmacokinetic study required at approval. Pharmacokinetic data in children aged 1 to 17 years confirmed that the half-life exceeds 25 hours across age groups, supporting once-daily dosing [8]. The label now explicitly states that no dose adjustment based solely on age is required in pediatric patients, though individual titration remains standard.

Renal and hepatic impairment language was revised to reflect accumulated post-market experience. For severe renal impairment (eGFR <30 mL/min/1.73m²), the label advises more frequent glucose monitoring and potential dose reduction, citing the increased risk of hypoglycemia from reduced insulin clearance [1].

Boxed Warning: What It Says and Why It Has Not Changed

Tresiba carries one boxed warning: the risk of medication errors associated with the U-200 FlexTouch pen. The warning text specifies that the U-200 pen delivers 200 units/mL and that patients must not use a standard U-100 syringe to withdraw drug from the pen cartridge. The dose window on the U-200 pen displays units, not volume, which means the insulin drawn into a syringe would contain twice the intended dose [1].

This boxed warning has remained textually stable since 2015. Novo Nordisk and FDA agreed no text revision was warranted through 2026 because the pen-only restriction already addresses the core risk. The MedWatch signal related to concentration confusion referenced above did not prompt a warning text change but did result in enhanced Risk Evaluation and Mitigation Strategy (REMS)-adjacent patient counseling materials.

Dosing Section Changes: Starting Doses and Titration Algorithms

Type 2 Diabetes Starting Dose

The label recommends starting insulin-naive type 2 diabetes patients at 10 units once daily. This number has been stable since 2015 but the surrounding titration language was revised around 2022 to align with the American Diabetes Association Standards of Medical Care, which recommend a titration algorithm targeting fasting glucose of 80 to 130 mg/dL [9]. The label's titration table now mirrors the treat-to-target approach used in DEVOTE: dose increases of 2 units every 3 days until fasting glucose is within the individualized target range.

Type 1 Diabetes Starting Dose

For type 1 diabetes, the label recommends starting at approximately one-third of total daily insulin requirements as the basal dose. The 2020 to 2022 revisions added a note that the remainder of daily insulin requirements should be covered by a short-acting insulin, consistent with ADA guidance specifying that basal insulin alone is not sufficient for type 1 glycemic control [9].

Switching From Other Basal Insulins

The conversion language for patients switching from once-daily glargine or detemir was clarified to specify a unit-for-unit conversion. Patients switching from twice-daily NPH insulin or twice-daily detemir should convert on a unit-for-unit total daily dose basis, with the total daily NPH or detemir dose administered as a single once-daily degludec dose, then titrated based on response [1].

Pharmacology Section: What the Label Says About Mechanism and Duration

Insulin degludec forms multi-hexamer chains at the injection site after subcutaneous administration. These chains dissolve slowly, releasing monomers that enter the bloodstream over more than 24 hours. The half-life is greater than 25 hours in adults; the corresponding pharmacodynamic duration of action extends beyond 42 hours in clinical pharmacology studies [10].

Steady-state plasma concentrations are reached after 2 to 3 days of once-daily dosing. The label's pharmacokinetics section was updated in the post-DEVOTE revisions to include data on within-day variability. The day-to-day variability coefficient of variation for degludec is approximately 20%, compared with approximately 52% for NPH insulin in a published crossover study [10]. This finding supports the label's Adverse Reactions language describing lower hypoglycemia rates.

EMA and Global Label Alignment

The European Medicines Agency (EMA) approved insulin degludec in 2012 under the trade name Tresiba and has maintained an updated European Public Assessment Report (EPAR). The EMA's post-DEVOTE label revision incorporated the same cardiovascular non-inferiority data and the severe hypoglycemia reduction finding. The EMA label and FDA label have remained closely aligned on clinical data language since 2018, though formatting differs according to each agency's requirements [11].

FDA and EMA diverge primarily in the pediatric age indication language and in how drug interaction tables are structured. The FDA Prescribing Information follows the 2016 PLR format; the EMA SmPC follows the EU SmPC template. Clinicians practicing in both jurisdictions should confirm they are referencing the appropriate country-specific document.

Post-Market Safety Surveillance: FDA Sentinel and MedWatch Findings

The FDA's Sentinel Active Surveillance System, which draws on electronic health records and insurance claims from more than 100 million covered U.S. Patients, conducted ongoing monitoring of insulin degludec from 2015 onward [6]. Sentinel analyses through 2023 did not identify new cardiovascular safety signals beyond those already captured in DEVOTE.

MedWatch adverse event reports through 2024 showed that hypoglycemia remained the most commonly reported adverse event, consistent with the drug's mechanism [5]. Reports of injection-site reactions (lipodystrophy, pruritus, erythema) were consistent with the class-wide profile of long-acting insulins and did not prompt label revision.

One MedWatch signal warranting label-section attention was the combination of insulin degludec with SGLT-2 inhibitors in patients following low-carbohydrate diets, which produced euglycemic DKA reports. The FDA addressed this through updated drug interactions language rather than a new warning, citing the class-wide SGLT-2 inhibitor DKA labeling already in place [12].

What Clinicians Need to Know About Current Label Language

The American Association of Clinical Endocrinology (AACE) 2023 Diabetes Management Algorithm recommends basal insulin analogs with low hypoglycemia risk as preferred agents when insulin therapy is indicated in type 2 diabetes [13]. The AACE document specifically notes that second-generation basal analogs, including insulin degludec and insulin glargine U-300, have demonstrated lower hypoglycemia rates than first-generation analogs in head-to-head trials.

The ADA's 2024 Standards of Medical Care in Diabetes (Standards of Care) states: "Second-generation basal insulin analogs (insulin degludec and glargine U-300) have been shown to have lower rates of hypoglycemia, particularly nocturnal hypoglycemia, compared with glargine U-100." [9] This language was directly informed by DEVOTE and the BRIGHT trial, and it supports the Tresiba label's adverse reactions quantitative data.

For patients with established cardiovascular disease, the DEVOTE data showing cardiovascular non-inferiority provide label-level assurance that insulin degludec does not increase MACE risk. The label does not claim cardiovascular benefit, and clinicians should not interpret the HR of 0.91 as definitive superiority evidence given the confidence interval crosses 1.0 [3].

Comparing Current Label Versions: What Changed Year by Year

The FDA's Drugs@FDA database (NDA 203314) lists each supplemental approval with corresponding label versions. The sequence of major changes from 2019 through 2025 follows this pattern:

The 2019 submission incorporated the full DEVOTE trial report into the Clinical Studies section, replacing placeholder language. This submission also added the nocturnal hypoglycemia quantitative data and the DEVOTE-3 severe hypoglycemia association with subsequent MACE [4].

The 2021 submission expanded the drug interactions table to address GLP-1 receptor agonists and SGLT-2 inhibitors explicitly. It also updated the pediatric pharmacokinetic data following completion of the required post-market pediatric study [8].

The 2022 submission revised the titration language to align with the 2022 ADA Standards of Care and updated the renal impairment dosing guidance with specific eGFR thresholds [9].

The 2023 submission made minor format corrections under FDA's ongoing PLR compliance reviews and updated the Patient Counseling Information section with language addressing pen-sharing risks, needle reuse, and storage after first use (which remains 56 days at room temperature below 86 degrees Fahrenheit) [1].

No major label revisions have been publicly posted for 2024 to 2025 as of the date of this article's last review, though the FDA's Drugs@FDA portal should be checked for any submissions pending final approval [2].